H. Leufkens

First name
H.
Middle name
G.
Last name
Leufkens
van Staa, T. P., Geusens, P. ., Pols, H. A., de Laet, C. ., Leufkens, H. G., & Cooper, C. . (2005). A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. Qjm. http://doi.org/10.1093/qjmed/hci029
de Vries, F. ., van Staa, T. P., Bracke, M. S., Cooper, C. ., Leufkens, H. G., & Lammers, J. W. (2005). Severity of obstructive airway disease and risk of osteoporotic fracture. Eur Respir J. http://doi.org/10.1183/09031936.05.00058204
van Staa, T. P., Card, T. ., Logan, R. F., & Leufkens, H. G. (2005). 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. http://doi.org/10.1136/gut.2005.070896
van de Garde, E. M., Hak, E. ., Souverein, P. C., Hoes, A. W., van den Bosch, J. M., & Leufkens, H. G. (2006). Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax. http://doi.org/10.1136/thx.2006.062885
Handoko, K. B., Souverein, P. C., van Staa, T. P., Meyboom, R. H., Leufkens, H. G., Egberts, T. C., & van den Bemt, P. M. (2006). Risk of aplastic anemia in patients using antiepileptic drugs. Epilepsia. http://doi.org/10.1111/j.1528-1167.2006.00596.x
de Vries, F. ., Souverein, P. C., Cooper, C. ., Leufkens, H. G., & van Staa, T. P. (2007). Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands. Calcif Tissue Int. http://doi.org/10.1007/s00223-006-0213-1
van Staa, T. P., Geusens, P. ., Bijlsma, J. W., Leufkens, H. G., & Cooper, C. . (2006). Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. http://doi.org/10.1002/art.22117
Verdel, B. M., Souverein, P. C., Egberts, A. C., & Leufkens, H. G. (2006). Difference in risks of allergic reaction to sulfonamide drugs based on chemical structure. Ann Pharmacother. http://doi.org/10.1345/aph.1G642
de Vries, F. ., Bracke, M. ., Leufkens, H. G., Lammers, J. W., Cooper, C. ., & van Staa, T. P. (2007). Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. http://doi.org/10.1002/art.22294
van Staa, T. P., Geusens, P. ., Zhang, B. ., Leufkens, H. G., Boonen, A. ., & Cooper, C. . (2007). Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids. Rheumatology (Oxford). http://doi.org/10.1093/rheumatology/kel249